KROS
Keros TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Positive mid-stage clinical data and a partnership would materially de-risk the franchise, supporting >30% upside to the anchor within a few quarters.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta 0.0.
What can break
Clinical failure, regulatory delay, or short cash runway could compress valuation toward the low-teens or below, driven by binary outcomes and near-term dilution.
Momentum
12
Value
54
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $19.22 · Bull $23.58 · Bear $13.10
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-13 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $23.00
Why
Momentum12 · Δ7d +1.9
Value54 · Δ7d +0.1
Sentiment100 · Δ7d 0.0
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
12
34% active weight
Current posture
7d trendImproving
Δ7d
+1.9
Δ21d
+7.6
Value
54
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.3
Sentiment
100
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+1.7
Why this grade
Composite grade C. Momentum 12.3 / Value 53.8 / Sentiment 100.0
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$208.8M
Beta
0.87
Shares Out
30.47M
P/E (TTM)
11.6
P/S (TTM)
2.21
P/FCF (TTM)
6.27
Rev YoY
+3575.8%
EPS YoY
+87.3%
Gross Margin
-
Op Margin
+17.7%
Net Debt
-$559.93M
Current Ratio
29.86
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology